Pre-earnings options volume in Pac Bio is normal with calls leading puts 5:3. Implied volatility suggests the market is anticipating a move near 4.4%, or 49c, after results are released. Median move over the past eight quarters is 9.0%.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
- Pacific Biosciences initiated with a Neutral at UBS
- Pacific Biosciences 17.5M share Spot Secondary priced at $10.00
- Pacific Biosciences $150M Spot Secondary; price range $10.00-$10.25
- Pacific Biosciences announces $150M common stock offering